weight loss drugs

New combo drug from Novo Nordisk leads to more weight loss than semaglutide alone, according to late-stage trial findings. Image credit: Kristian Tuxen Ladegaard Berg/NurPhoto via Getty Images A new 68-week trial found that weekly injections with CagriSema resulted in weight loss of up to 14.2% compared with 10.2% for semaglutide (Wegovy). CagriSema also reduced

by Rachel Woods, The Conversation edited by Gaby Clark, reviewed by Andrew Zinin  Editors’ notes  The GIST Add as preferred source Credit: Unsplash/CC0 Public Domain Weight-loss drugs such as Ozempic, Wegovy and Mounjaro work primarily by reducing hunger. They mimic a hormone the body already produces called glucagon-like peptide-1 (GLP-1), which helps regulate appetite and feelings of fullness.

Marilynn Larkin November 04, 2025 Semaglutide, tirzepatide, and dulaglutide have similar gastrointestinal safety profiles among patients with type 2 diabetes (T2D), an active-comparator cohort study showed. “We were somewhat surprised by the fact that despite differences in receptor activity and potency, dulaglutide, semaglutide, and tirzepatide showed a remarkably similar risk of serious gastrointestinal events,” Elisabetta Patorno, MD, DrPH, of Brigham

By Bronwyn Thompson November 24, 2025 Facebook Twitter LinkedIn Reddit Flipboard Email Oral GLP-1 drugs are expected to have a big 2026 – but, sadly, it won’t be in treating Alzheimer’s disease Depositphotos View 1 Images Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer’s disease (AD), as two-year clinical

by Intermountain Healthcare edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by patients who have high triglycerides do not increase their risk of pancreatitis or adverse cardiac events. Credit: Intermountain Health In a major new study,